Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

Core Insights - Nexalin Technology, Inc. is initiating a new clinical trial for its Gen-3 Halo headset in collaboration with the University of California, San Diego, focusing on treating veterans with mild Traumatic Brain Injury (mTBI) through a virtual clinic model [1][2][5] - The Gen-3 Halo headset utilizes Nexalin's proprietary Deep Intracranial Frequency Stimulation (DIFS®) technology, featuring an advanced 15 milliamp waveform, aimed at enhancing convenience for in-home treatment while maintaining clinical precision [2][6] - The study aligns with the Veterans Administration's goal of expanding telehealth services for veterans, with over $17 billion allocated for mental health services in their 2025 Professional Judgement Budget [3] Study Design and Objectives - The trial will assess the effectiveness of the Gen-3 Halo headset by interpreting MEG signals and measuring changes in brain activity and symptom relief in veterans with mTBI [4][5] - Two participant groups will be recruited: Group 1 will receive treatment with the Gen-3 Halo headset, while Group 2 will be assigned a sham device for comparison [4] Enhanced Access to Care - The Gen-3 Halo headset represents a significant advancement in neuromodulation technology, designed for at-home use within a virtual clinic model, enhancing patient convenience and ensuring targeted treatment [6] - Previous trials using the Gen-2 console device showed notable improvements in brain activity and pain reduction among participants, laying the groundwork for the current study [6][7] Company Overview - Nexalin Technology designs and develops innovative neurostimulation products aimed at addressing the global mental health epidemic, with a focus on non-invasive treatments [7]